تولید دارو در برابر کروناویروس
ترجمه نشده

تولید دارو در برابر کروناویروس

عنوان فارسی مقاله: پیشرفت و چالش های اخیر در تولید دارو در برابر کروناویروس کووید ۱۹ (SARS-CoV-2) – به روز رسانی وضعیت
عنوان انگلیسی مقاله: Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) – an update on the status
مجله/کنفرانس: عفونت ، ژنتیک و تکامل – Infection, Genetics and Evolution
رشته های تحصیلی مرتبط: پزشکی، داروسازی
گرایش های تحصیلی مرتبط: ویروس شناسی پزشکی، بیماری های عفونی، ایمنی شناسی پزشکی یا ایمونولوژی، پزشکی مولوکولی، اپیدمیولوژی یا همه گیر شناسی، داروسازی بالینی
کلمات کلیدی فارسی: کروناویروس، کروناویروس سارس ۲، کووید ۱۹، سندرم حاد تنفسی، پاتوژنز، درمان، واکسن
کلمات کلیدی انگلیسی: Coronavirus، SARS-CoV-2، COVID-19، Severe acute respiratory syndrome، Pathogenesis، Therapy، Vaccines
نوع نگارش مقاله: مقاله مروری (Review Article)
نمایه: Scopus – Master Journals List – JCR
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.meegid.2020.104327
دانشگاه: Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229-3900, USA
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2020
ایمپکت فاکتور: 2.670 در سال 2019
شاخص H_index: 74 در سال 2020
شاخص SJR: 1.208 در سال 2019
شناسه ISSN: 1567-1348
شاخص Quartile (چارک): Q2 در سال 2019
فرمت مقاله انگلیسی: PDF
تعداد صفحات مقاله انگلیسی: 10
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E14858
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست انگلیسی مطالب

Abstract


Abbreviations


۱٫ Introduction


۲٫ Origin and transmission


۳٫ Symptoms


۴٫ Epidemiology


۵٫ Therapeutics and available treatment options


۶٫ Guidelines to prevent the spread of SARS-CoV-2 infection


۷٫ Conclusion


Ethical approval


Sources of funding


Author contribution


Declaration of Competing Interest


Acknowledgements


References

نمونه متن انگلیسی مقاله

Abstract


Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People’s Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.


Introduction


In the second week of December 2019, unknown viral infection was identified in a small local fish and wild animal market in Wuhan city, Hubei province in China (Lu et al., 2020). Since this time, the virus has rapidly spread across mainland China, and now has reached other countries (Li et al., 2020a; Chen et al., 2020a). In the early stages of this virus spread, several cases of pneumonia of unknown etiology were reported. Patients have been diagnosed with severe acute respiratory infection symptoms and others with rapidly developing acute respiratory distress syndrome, acute respiratory failure and other serious complications leading to death (Nijuan et al., 2013). The Chinese Center for Disease Control and Prevention (CCDC) identified this infection as a novel coronavirus infection on Jan 7, 2020 and on Feb 11, 2020, the WHO announced a new name for the epidemic disease as 2019-new coronavirus disease (2019-nCoV and now known as COVID19) (Organization, W.H., 2020). Additionally, the International Committee on Taxonomy of Viruses named 2019-nCoV as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has become a major global health concern and the WHO declared the coronavirus outbreak a global pandemic on March 2020 (Whitworth, 2020). As of April 14, 2020, COVID-19 has affected more than 1,948,617 patients in 210 countries and territories around the world and two international conveyances and left around 121,846 deaths worldwide.

  • اشتراک گذاری در

دیدگاه خود را بنویسید:

تاکنون دیدگاهی برای این نوشته ارسال نشده است

تولید دارو در برابر کروناویروس
نوشته های مرتبط
مقالات جدید
لوگوی رسانه های برخط

logo-samandehi

پیوندها